{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T11:19:10Z","timestamp":1794827950362,"version":"4.9.1"},"reference-count":119,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Chem"],"DOI":"10.1038\/s41570-025-00770-y","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T16:57:49Z","timestamp":1764089869000},"page":"841-854","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Chemical strategies for brain delivery of genomic therapy"],"prefix":"10.1038","volume":"9","author":[{"given":"Haoyuan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyue","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Markovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7905-2000","authenticated-orcid":false,"given":"Eric J.","family":"Nestler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5786-0659","authenticated-orcid":false,"given":"Yizhou","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"770_CR1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1238411","volume":"342","author":"HJ Park","year":"2013","unstructured":"Park, H. J. & Friston, K. Structural and functional brain networks: from connections to cognition. Science 342, 1238411 (2013).","journal-title":"Science"},{"key":"770_CR2","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/s41593-020-00778-1","volume":"24","author":"J Sun","year":"2021","unstructured":"Sun, J. & Roy, S. Gene-based therapies for neurodegenerative diseases. Nat. Neurosci. 24, 297\u2013311 (2021).","journal-title":"Nat. Neurosci."},{"key":"770_CR3","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/S1474-4422(23)00277-6","volume":"22","author":"VL Feigin","year":"2023","unstructured":"Feigin, V. L., Owolabi, M. O. & World Stroke Organization-Lancet Neurology Commission Stroke Collaboration Group Pragmatic solutions to reduce the global burden of stroke: a World Stroke Organization-Lancet Neurology Commission. Lancet Neurol. 22, 1160\u20131206 (2023).","journal-title":"Lancet Neurol."},{"key":"770_CR4","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nrn3381","volume":"14","author":"SJ Russo","year":"2013","unstructured":"Russo, S. J. & Nestler, E. J. The brain reward circuitry in mood disorders. Nat. Rev. Neurosci. 14, 609\u2013625 (2013).","journal-title":"Nat. Rev. Neurosci."},{"key":"770_CR5","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1001\/jama.2023.0023","volume":"329","author":"LR Schaff","year":"2023","unstructured":"Schaff, L. R. & Mellinghoff, I. K. Glioblastoma and other primary brain malignancies in adults: a review. JAMA 329, 574\u2013587 (2023).","journal-title":"JAMA"},{"key":"770_CR6","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41582-020-0389-4","volume":"16","author":"SJ Tabrizi","year":"2020","unstructured":"Tabrizi, S. J., Flower, M. D., Ross, C. A. & Wild, E. J. Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities. Nat. Rev. Neurol. 16, 529\u2013546 (2020).","journal-title":"Nat. Rev. Neurol."},{"key":"770_CR7","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s13311-022-01247-2","volume":"19","author":"BD Boros","year":"2022","unstructured":"Boros, B. D., Schoch, K. M., Kreple, C. J. & Miller, T. M. Antisense oligonucleotides for the study and treatment of ALS. Neurotherapeutics 19, 1145\u20131158 (2022).","journal-title":"Neurotherapeutics"},{"key":"770_CR8","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S1474-4422(20)30217-9","volume":"19","author":"AJ Sandweiss","year":"2020","unstructured":"Sandweiss, A. J., Brandt, V. L. & Zoghbi, H. Y. Advances in understanding of Rett syndrome and MECP2 duplication syndrome: prospects for future therapies. Lancet Neurol. 19, 689\u2013698 (2020).","journal-title":"Lancet Neurol."},{"key":"770_CR9","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1038\/s41587-021-01108-x","volume":"39","author":"Y Wang","year":"2021","unstructured":"Wang, Y., Zhao, Y., Bollas, A., Wang, Y. & Au, K. F. Nanopore sequencing technology, bioinformatics and applications. Nat. Biotechnol. 39, 1348\u20131365 (2021).","journal-title":"Nat. Biotechnol."},{"key":"770_CR10","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","volume":"19","author":"TC Roberts","year":"2020","unstructured":"Roberts, T. C., Langer, R. & Wood, M. J. A. Advances in oligonucleotide drug delivery. Nat. Rev. Drug Discov. 19, 673\u2013694 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"770_CR11","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41573-021-00139-y","volume":"20","author":"GC Terstappen","year":"2021","unstructured":"Terstappen, G. C., Meyer, A. H., Bell, R. D. & Zhang, W. Strategies for delivering therapeutics across the blood-brain barrier. Nat. Rev. Drug Discov. 20, 362\u2013383 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"770_CR12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.cell.2019.02.003","volume":"177","author":"J Shendure","year":"2019","unstructured":"Shendure, J., Findlay, G. M. & Snyder, M. W. Genomic medicine \u2014 progress, pitfalls, and promise. Cell 177, 45\u201357 (2019).","journal-title":"Cell"},{"key":"770_CR13","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","volume":"387","author":"TM Miller","year":"2022","unstructured":"Miller, T. M. et al. Trial of antisense oligonucleotide tofersen for SOD1 ALS. N. Engl. J. Med. 387, 1099\u20131110 (2022).","journal-title":"N. Engl. J. Med."},{"key":"770_CR14","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ymthe.2021.11.005","volume":"30","author":"CH Tai","year":"2022","unstructured":"Tai, C. H. et al. Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency. Mol. Ther. 30, 509\u2013518 (2022).","journal-title":"Mol. Ther."},{"key":"770_CR15","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/s41578-021-00394-w","volume":"7","author":"E Nance","year":"2022","unstructured":"Nance, E., Pun, S. H., Saigal, R. & Sellers, D. L. Drug delivery to the central nervous system. Nat. Rev. Mater. 7, 314\u2013331 (2022).","journal-title":"Nat. Rev. Mater."},{"key":"770_CR16","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1126\/science.adm8386","volume":"384","author":"Q Huang","year":"2024","unstructured":"Huang, Q. et al. An AAV capsid reprogrammed to bind human transferrin receptor mediates brain-wide gene delivery. Science 384, 1220\u20131227 (2024).","journal-title":"Science"},{"key":"770_CR17","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/nn.4593","volume":"20","author":"KY Chan","year":"2017","unstructured":"Chan, K. Y. et al. Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. Nat. Neurosci. 20, 1172\u20131179 (2017).","journal-title":"Nat. Neurosci."},{"key":"770_CR18","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nbt.3440","volume":"34","author":"BE Deverman","year":"2016","unstructured":"Deverman, B. E. et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204\u2013209 (2016).","journal-title":"Nat. Biotechnol."},{"key":"770_CR19","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41583-024-00829-7","volume":"25","author":"J Gao","year":"2024","unstructured":"Gao, J. et al. Gene therapy for CNS disorders: modalities, delivery and translational challenges. Nat. Rev. Neurosci. 25, 553\u2013572 (2024).","journal-title":"Nat. Rev. Neurosci."},{"key":"770_CR20","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","volume":"29","author":"JR Mendell","year":"2021","unstructured":"Mendell, J. R. et al. Current clinical applications of in vivo gene therapy with AAVs. Mol. Ther. 29, 464\u2013488 (2021).","journal-title":"Mol. Ther."},{"key":"770_CR21","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1146\/annurev-neuro-111020-100834","volume":"45","author":"RC Challis","year":"2022","unstructured":"Challis, R. C. et al. Adeno-associated virus toolkit to target diverse brain cells. Annu. Rev. Neurosci. 45, 447\u2013469 (2022).","journal-title":"Annu. Rev. Neurosci."},{"key":"770_CR22","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","volume":"14","author":"A Akinc","year":"2019","unstructured":"Akinc, A. et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat. Nanotechnol. 14, 1084\u20131087 (2019).","journal-title":"Nat. Nanotechnol."},{"key":"770_CR23","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"770_CR24","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"770_CR25","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"X Hou","year":"2021","unstructured":"Hou, X., Zaks, T., Langer, R. & Dong, Y. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 6, 1078\u20131094 (2021).","journal-title":"Nat. Rev. Mater."},{"key":"770_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50619-z","volume":"15","author":"Y Xu","year":"2024","unstructured":"Xu, Y. et al. AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery. Nat. Commun. 15, 6305 (2024).","journal-title":"Nat. Commun."},{"key":"770_CR27","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1073\/pnas.1620874114","volume":"114","author":"JE Dahlman","year":"2017","unstructured":"Dahlman, J. E. et al. Barcoded nanoparticles for high throughput in vivo discovery of targeted therapeutics. Proc. Natl Acad. Sci. USA 114, 2060\u20132065 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"770_CR28","doi-asserted-by":"publisher","first-page":"9126","DOI":"10.1007\/s12274-024-6827-7","volume":"17","author":"Y Kuzminich","year":"2024","unstructured":"Kuzminich, Y. et al. Lipid nanoparticles deliver mRNA to the blood\u2013brain barrier. Nano Res. 17, 9126\u20139134 (2024).","journal-title":"Nano Res."},{"key":"770_CR29","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1021\/acs.nanolett.3c03509","volume":"24","author":"EL Han","year":"2024","unstructured":"Han, E. L. et al. Predictive high-throughput platform for dual screening of mRNA lipid nanoparticle blood-brain barrier transfection and crossing. Nano Lett. 24, 1477\u20131486 (2024).","journal-title":"Nano Lett."},{"key":"770_CR30","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1038\/s41596-018-0066-x","volume":"13","author":"S Bergmann","year":"2018","unstructured":"Bergmann, S. et al. Blood-brain-barrier organoids for investigating the permeability of CNS therapeutics. Nat. Protoc. 13, 2827\u20132843 (2018).","journal-title":"Nat. Protoc."},{"key":"770_CR31","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.stem.2024.04.019","volume":"31","author":"L Dao","year":"2024","unstructured":"Dao, L. et al. Modeling blood-brain barrier formation and cerebral cavernous malformations in human PSC-derived organoids. Cell Stem Cell 31, 818\u2013833.e11 (2024).","journal-title":"Cell Stem Cell"},{"key":"770_CR32","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/s41551-023-01030-4","volume":"7","author":"LH Rhym","year":"2023","unstructured":"Rhym, L. H., Manan, R. S., Koller, A., Stephanie, G. & Anderson, D. G. Peptide-encoding mRNA barcodes for the high-throughput in vivo screening of libraries of lipid nanoparticles for mRNA delivery. Nat. Biomed. Eng. 7, 901\u2013910 (2023).","journal-title":"Nat. Biomed. Eng."},{"key":"770_CR33","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abb4429","volume":"6","author":"F Ma","year":"2020","unstructured":"Ma, F. et al. Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection. Sci. Adv. 6, eabb4429 (2020).","journal-title":"Sci. Adv."},{"key":"770_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-024-04506-9","author":"HS Ahmed","year":"2024","unstructured":"Ahmed, H. S. The multifaceted role of L-type amino acid transporter 1 at the blood-brain barrier: structural implications and therapeutic potential. Mol. Neurobiol. https:\/\/doi.org\/10.1007\/s12035-024-04506-9 (2024).","journal-title":"Mol. Neurobiol."},{"key":"770_CR35","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.neuint.2012.03.008","volume":"60","author":"P Pernot","year":"2012","unstructured":"Pernot, P. et al. D-Serine diffusion through the blood-brain barrier: effect on D-serine compartmentalization and storage. Neurochem. Int. 60, 837\u2013845 (2012).","journal-title":"Neurochem. Int."},{"key":"770_CR36","doi-asserted-by":"publisher","unstructured":"Strobel, H. et al. Temozolomide and other alkylating agents in glioblastoma therapy. Biomedicines https:\/\/doi.org\/10.3390\/biomedicines7030069 (2019).","DOI":"10.3390\/biomedicines7030069"},{"key":"770_CR37","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.brainresbull.2016.04.016","volume":"126","author":"TM Carbonaro","year":"2016","unstructured":"Carbonaro, T. M. & Gatch, M. B. Neuropharmacology of N,N-dimethyltryptamine. Brain Res. Bull. 126, 74\u201388 (2016).","journal-title":"Brain Res. Bull."},{"key":"770_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25010582","volume":"25","author":"A Drakontaeidi","year":"2024","unstructured":"Drakontaeidi, A. & Pontiki, E. Multi-target-directed cinnamic acid hybrids targeting Alzheimer\u2019s disease. Int. J. Mol. Sci. 25, 582 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"770_CR39","doi-asserted-by":"publisher","first-page":"6743","DOI":"10.1523\/JNEUROSCI.1381-10.2010","volume":"30","author":"JJ Cook","year":"2010","unstructured":"Cook, J. J. et al. Acute \u03b3-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-\u03b2 production to alternative APP fragments without amyloid-\u03b2 rebound. J. Neurosci. 30, 6743\u20136750 (2010).","journal-title":"J. Neurosci."},{"key":"770_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41563-024-02114-5","author":"C Wang","year":"2025","unstructured":"Wang, C. et al. Blood-brain-barrier-crossing lipid nanoparticles for mRNA delivery to the central nervous system. Nat. Mater. https:\/\/doi.org\/10.1038\/s41563-024-02114-5 (2025).","journal-title":"Nat. Mater."},{"key":"770_CR41","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/nn.3871","volume":"17","author":"EA Heller","year":"2014","unstructured":"Heller, E. A. et al. Locus-specific epigenetic remodeling controls addiction- and depression-related behaviors. Nat. Neurosci. 17, 1720\u20131727 (2014).","journal-title":"Nat. Neurosci."},{"key":"770_CR42","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adw0730","volume":"11","author":"D Cao","year":"2025","unstructured":"Cao, D. et al. Lipid nanoparticles for mRNA delivery in brain via systemic administration. Sci. Adv. 11, eadw0730 (2025).","journal-title":"Sci. Adv."},{"key":"770_CR43","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.ymthe.2024.03.004","volume":"32","author":"J Nong","year":"2024","unstructured":"Nong, J. et al. Targeting lipid nanoparticles to the blood-brain barrier to ameliorate acute ischemic stroke. Mol. Ther. 32, 1344\u20131358 (2024).","journal-title":"Mol. Ther."},{"key":"770_CR44","doi-asserted-by":"publisher","DOI":"10.1021\/acs.nanolett.4c05186","author":"EL Han","year":"2024","unstructured":"Han, E. L. et al. Peptide-functionalized lipid nanoparticles for targeted systemic mRNA delivery to the brain. Nano Lett. https:\/\/doi.org\/10.1021\/acs.nanolett.4c05186 (2024).","journal-title":"Nano Lett."},{"key":"770_CR45","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abd6889","volume":"7","author":"W Li","year":"2021","unstructured":"Li, W. et al. BBB pathophysiology-independent delivery of siRNA in traumatic brain injury. Sci. Adv. 7, eabd6889 (2021).","journal-title":"Sci. Adv."},{"key":"770_CR46","doi-asserted-by":"publisher","first-page":"5357","DOI":"10.1016\/j.cell.2024.07.023","volume":"187","author":"DW Brown","year":"2024","unstructured":"Brown, D. W. et al. Safe and effective in vivo delivery of DNA and RNA using proteolipid vehicles. Cell 187, 5357\u20135375.e24 (2024).","journal-title":"Cell"},{"key":"770_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/srep20019","volume":"6","author":"JF Nabhan","year":"2016","unstructured":"Nabhan, J. F. et al. Intrathecal delivery of frataxin mRNA encapsulated in lipid nanoparticles to dorsal root ganglia as a potential therapeutic for Friedreich\u2019s ataxia. Sci. Rep. 6, 20019 (2016).","journal-title":"Sci. Rep."},{"key":"770_CR48","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abc9450","volume":"6","author":"D Rosenblum","year":"2020","unstructured":"Rosenblum, D. et al. CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. Sci. Adv. 6, eabc9450 (2020).","journal-title":"Sci. Adv."},{"key":"770_CR49","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1021\/acs.molpharmaceut.0c00170","volume":"17","author":"HK Dhaliwal","year":"2020","unstructured":"Dhaliwal, H. K., Fan, Y., Kim, J. & Amiji, M. M. Intranasal delivery and transfection of mRNA therapeutics in the brain using cationic liposomes. Mol. Pharm. 17, 1996\u20132005 (2020).","journal-title":"Mol. Pharm."},{"key":"770_CR50","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2302910120","volume":"120","author":"YH Lao","year":"2023","unstructured":"Lao, Y. H. et al. Focused ultrasound-mediated brain genome editing. Proc. Natl Acad. Sci. USA 120, e2302910120 (2023).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"770_CR51","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jconrel.2022.05.042","volume":"348","author":"K Ogawa","year":"2022","unstructured":"Ogawa, K. et al. Focused ultrasound\/microbubbles-assisted BBB opening enhances LNP-mediated mRNA delivery to brain. J. Control. Release 348, 34\u201341 (2022).","journal-title":"J. Control. Release"},{"key":"770_CR52","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1695","volume":"13","author":"X Zhou","year":"2021","unstructured":"Zhou, X., Smith, Q. R. & Liu, X. Brain penetrating peptides and peptide-drug conjugates to overcome the blood-brain barrier and target CNS diseases. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 13, e1695 (2021).","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"770_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13122045","volume":"13","author":"L Ribovski","year":"2021","unstructured":"Ribovski, L., Hamelmann, N. M. & Paulusse, J. M. J. Polymeric nanoparticles properties and brain delivery. Pharmaceutics 13, 2045 (2021).","journal-title":"Pharmaceutics"},{"key":"770_CR54","doi-asserted-by":"publisher","first-page":"6832","DOI":"10.1016\/j.biomaterials.2011.05.064","volume":"32","author":"S Huang","year":"2011","unstructured":"Huang, S. et al. Dual targeting effect of Angiopep-2-modified, DNA-loaded nanoparticles for glioma. Biomaterials 32, 6832\u20136838 (2011).","journal-title":"Biomaterials"},{"key":"770_CR55","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.jconrel.2016.10.027","volume":"243","author":"S Gao","year":"2016","unstructured":"Gao, S. et al. A non-viral suicide gene delivery system traversing the blood brain barrier for non-invasive glioma targeting treatment. J. Control. Release 243, 357\u2013369 (2016).","journal-title":"J. Control. Release"},{"key":"770_CR56","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abm8011","volume":"8","author":"Y Zou","year":"2022","unstructured":"Zou, Y. et al. Blood-brain barrier-penetrating single CRISPR-Cas9 nanocapsules for effective and safe glioblastoma gene therapy. Sci. Adv. 8, eabm8011 (2022).","journal-title":"Sci. Adv."},{"key":"770_CR57","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1158\/1535-7163.MCT-11-0566","volume":"11","author":"R Kurzrock","year":"2012","unstructured":"Kurzrock, R. et al. Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of Angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors. Mol. Cancer Ther. 11, 308\u2013316 (2012).","journal-title":"Mol. Cancer Ther."},{"key":"770_CR58","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jconrel.2010.08.011","volume":"155","author":"S Son","year":"2011","unstructured":"Son, S. et al. RVG peptide tethered bioreducible polyethylenimine for gene delivery to brain. J. Control. Release 155, 18\u201325 (2011).","journal-title":"J. Control. Release"},{"key":"770_CR59","doi-asserted-by":"publisher","first-page":"4195","DOI":"10.1016\/j.biomaterials.2009.02.051","volume":"30","author":"Y Liu","year":"2009","unstructured":"Liu, Y. et al. Brain-targeting gene delivery and cellular internalization mechanisms for modified rabies virus glycoprotein RVG29 nanoparticles. Biomaterials 30, 4195\u20134202 (2009).","journal-title":"Biomaterials"},{"key":"770_CR60","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jconrel.2018.04.034","volume":"279","author":"P Wang","year":"2018","unstructured":"Wang, P. et al. Systemic delivery of BACE1 siRNA through neuron-targeted nanocomplexes for treatment of Alzheimer\u2019s disease. J. Control. Release 279, 220\u2013233 (2018).","journal-title":"J. Control. Release"},{"key":"770_CR61","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.2174\/1389201022666210104115224","volume":"22","author":"VM Suarez","year":"2021","unstructured":"Suarez, V. M., Vispo, N. S. & Ramos, O. S. Application of the phage display technology for the development of peptide-mediated drug delivery systems through the blood-brain barrier. Curr. Pharm. Biotechnol. 22, 1394\u20131403 (2021).","journal-title":"Curr. Pharm. Biotechnol."},{"key":"770_CR62","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41586-024-07935-7","volume":"633","author":"K Motone","year":"2024","unstructured":"Motone, K. et al. Multi-pass, single-molecule nanopore reading of long protein strands. Nature 633, 662\u2013669 (2024).","journal-title":"Nature"},{"key":"770_CR63","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.biomaterials.2007.09.024","volume":"29","author":"R Huang","year":"2008","unstructured":"Huang, R., Ke, W., Liu, Y., Jiang, C. & Pei, Y. The use of lactoferrin as a ligand for targeting the polyamidoamine-based gene delivery system to the brain. Biomaterials 29, 238\u2013246 (2008).","journal-title":"Biomaterials"},{"key":"770_CR64","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jns.2009.09.032","volume":"290","author":"R Huang","year":"2010","unstructured":"Huang, R. et al. Gene therapy using lactoferrin-modified nanoparticles in a rotenone-induced chronic Parkinson model. J. Neurol. Sci. 290, 123\u2013130 (2010).","journal-title":"J. Neurol. Sci."},{"key":"770_CR65","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/jnr.22738","volume":"89","author":"K Devraj","year":"2011","unstructured":"Devraj, K. et al. GLUT-1 glucose transporters in the blood-brain barrier: differential phosphorylation. J. Neurosci. Res. 89, 1913\u20131925 (2011).","journal-title":"J. Neurosci. Res."},{"key":"770_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00952-3","volume":"8","author":"Y Anraku","year":"2017","unstructured":"Anraku, Y. et al. Glycaemic control boosts glucosylated nanocarrier crossing the BBB into the brain. Nat. Commun. 8, 1001 (2017).","journal-title":"Nat. Commun."},{"key":"770_CR67","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jconrel.2019.02.021","volume":"301","author":"K Suzuki","year":"2019","unstructured":"Suzuki, K. et al. Glucose transporter 1-mediated vascular translocation of nanomedicines enhances accumulation and efficacy in solid tumors. J. Control. Release 301, 28\u201341 (2019).","journal-title":"J. Control. Release"},{"key":"770_CR68","doi-asserted-by":"publisher","first-page":"8173","DOI":"10.1002\/anie.201914751","volume":"59","author":"HS Min","year":"2020","unstructured":"Min, H. S. et al. Systemic brain delivery of antisense oligonucleotides across the blood-brain barrier with a glucose-coated polymeric nanocarrier. Angew. Chem. Int. Ed. 59, 8173\u20138180 (2020).","journal-title":"Angew. Chem. Int. Ed."},{"key":"770_CR69","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jconrel.2022.08.049","volume":"350","author":"M Kim","year":"2022","unstructured":"Kim, M. et al. Delivery of self-replicating messenger RNA into the brain for the treatment of ischemic stroke. J. Control. Release 350, 471\u2013485 (2022).","journal-title":"J. Control. Release"},{"key":"770_CR70","doi-asserted-by":"publisher","first-page":"3524","DOI":"10.1016\/j.xphs.2017.07.020","volume":"106","author":"J Oh","year":"2017","unstructured":"Oh, J., Lee, M. S., Jeong, J. H. & Lee, M. Deoxycholic acid-conjugated polyethylenimine for delivery of heme oxygenase-1 gene in rat ischemic stroke model. J. Pharm. Sci. 106, 3524\u20133532 (2017).","journal-title":"J. Pharm. Sci."},{"key":"770_CR71","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1002\/smll.201502930","volume":"12","author":"Y Cheng","year":"2016","unstructured":"Cheng, Y. et al. Nano-sized sunflower polycations as effective gene transfer vehicles. Small 12, 2750\u20132758 (2016).","journal-title":"Small"},{"key":"770_CR72","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/bit.28269","volume":"120","author":"M Sadeqi Nezhad","year":"2023","unstructured":"Sadeqi Nezhad, M. Poly (beta-amino ester) as an in vivo nanocarrier for therapeutic nucleic acids. Biotechnol. Bioeng. 120, 95\u2013113 (2023).","journal-title":"Biotechnol. Bioeng."},{"key":"770_CR73","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.201801359","volume":"8","author":"Y Liu","year":"2019","unstructured":"Liu, Y., Li, Y., Keskin, D. & Shi, L. Poly(beta-amino esters): synthesis, formulations, and their biomedical applications. Adv. Healthc. Mater. 8, e1801359 (2019).","journal-title":"Adv. Healthc. Mater."},{"key":"770_CR74","doi-asserted-by":"publisher","first-page":"5141","DOI":"10.1021\/nn501197v","volume":"8","author":"H Guerrero-Cazares","year":"2014","unstructured":"Guerrero-Cazares, H. et al. Biodegradable polymeric nanoparticles show high efficacy and specificity at DNA delivery to human glioblastoma in vitro and in vivo. ACS Nano 8, 5141\u20135153 (2014).","journal-title":"ACS Nano"},{"key":"770_CR75","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1021\/acs.biomac.2c00137","volume":"23","author":"Q Chen","year":"2022","unstructured":"Chen, Q. et al. Poly(beta-amino ester)-based nanoparticles enable nonviral delivery of base editors for targeted tumor gene editing. Biomacromolecules 23, 2116\u20132125 (2022).","journal-title":"Biomacromolecules"},{"key":"770_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.cej.2023.143152","volume":"466","author":"H Li","year":"2023","unstructured":"Li, H. et al. Engineering brain-derived neurotrophic factor mRNA delivery for the treatment of Alzheimer\u2019s disease. Chem. Eng. J. 466, 143152 (2023).","journal-title":"Chem. Eng. J."},{"key":"770_CR77","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel, R. S. et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N. Engl. J. Med. 377, 1723\u20131732 (2017).","journal-title":"N. Engl. J. Med."},{"key":"770_CR78","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adi2245","volume":"16","author":"SJ Barker","year":"2024","unstructured":"Barker, S. J. et al. Targeting the transferrin receptor to transport antisense oligonucleotides across the mammalian blood-brain barrier. Sci. Transl. Med. 16, eadi2245 (2024).","journal-title":"Sci. Transl. Med."},{"key":"770_CR79","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/s41587-021-00972-x","volume":"39","author":"T Nagata","year":"2021","unstructured":"Nagata, T. et al. Cholesterol-functionalized DNA\/RNA heteroduplexes cross the blood-brain barrier and knock down genes in the rodent CNS. Nat. Biotechnol. 39, 1529\u20131536 (2021).","journal-title":"Nat. Biotechnol."},{"key":"770_CR80","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1038\/jcbfm.2012.126","volume":"32","author":"WM Pardridge","year":"2012","unstructured":"Pardridge, W. M. Drug transport across the blood-brain barrier. J. Cereb. Blood Flow Metab. 32, 1959\u20131972 (2012).","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"770_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-024-02487-7","author":"C Wang","year":"2024","unstructured":"Wang, C. et al. Intravenous administration of blood-brain barrier-crossing conjugates facilitate biomacromolecule transport into central nervous system. Nat. Biotechnol. https:\/\/doi.org\/10.1038\/s41587-024-02487-7 (2024).","journal-title":"Nat. Biotechnol."},{"key":"770_CR82","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams, D. et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N. Engl. J. Med. 379, 11\u201321 (2018).","journal-title":"N. Engl. J. Med."},{"key":"770_CR83","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","volume":"382","author":"M Balwani","year":"2020","unstructured":"Balwani, M. et al. Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria. N. Engl. J. Med. 382, 2289\u20132301 (2020).","journal-title":"N. Engl. J. Med."},{"key":"770_CR84","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202208018","volume":"35","author":"Y Wang","year":"2023","unstructured":"Wang, Y. et al. Overcoming the blood-brain barrier for gene therapy via systemic administration of GSH-responsive silica nanocapsules. Adv. Mater. 35, e2208018 (2023).","journal-title":"Adv. Mater."},{"key":"770_CR85","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1038\/s41587-022-01334-x","volume":"40","author":"KM Brown","year":"2022","unstructured":"Brown, K. M. et al. Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates. Nat. Biotechnol. 40, 1500\u20131508 (2022).","journal-title":"Nat. Biotechnol."},{"key":"770_CR86","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1038\/s41587-019-0205-0","volume":"37","author":"JF Alterman","year":"2019","unstructured":"Alterman, J. F. et al. A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system. Nat. Biotechnol. 37, 884\u2013894 (2019).","journal-title":"Nat. Biotechnol."},{"key":"770_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-024-02336-7","author":"K Yamada","year":"2024","unstructured":"Yamada, K. et al. Enhancing siRNA efficacy in vivo with extended nucleic acid backbones. Nat. Biotechnol. https:\/\/doi.org\/10.1038\/s41587-024-02336-7 (2024).","journal-title":"Nat. Biotechnol."},{"key":"770_CR88","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.154142","volume":"7","author":"SM Hammond","year":"2022","unstructured":"Hammond, S. M. et al. Antibody-oligonucleotide conjugate achieves CNS delivery in animal models for spinal muscular atrophy. JCI Insight 7, e154142 (2022).","journal-title":"JCI Insight"},{"key":"770_CR89","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40272-022-00529-8","volume":"24","author":"CA Chiriboga","year":"2022","unstructured":"Chiriboga, C. A. Pharmacotherapy for spinal muscular atrophy in babies and children: a review of approved and experimental therapies. Paediatr. Drugs 24, 585\u2013602 (2022).","journal-title":"Paediatr. Drugs"},{"key":"770_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2023.127060","volume":"253","author":"R Heidari","year":"2023","unstructured":"Heidari, R., Assadollahi, V., Khosravian, P., Mirzaei, S. A. & Elahian, F. Engineered mesoporous silica nanoparticles, new insight nanoplatforms into effective cancer gene therapy. Int. J. Biol. Macromol. 253, 127060 (2023).","journal-title":"Int. J. Biol. Macromol."},{"key":"770_CR91","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41551-023-01150-x","volume":"8","author":"W Gu","year":"2024","unstructured":"Gu, W. et al. Extracellular vesicles incorporating retrovirus-like capsids for the enhanced packaging and systemic delivery of mRNA into neurons. Nat. Biomed. Eng. 8, 415\u2013426 (2024).","journal-title":"Nat. Biomed. Eng."},{"key":"770_CR92","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41551-019-0485-1","volume":"4","author":"Z Yang","year":"2020","unstructured":"Yang, Z. et al. Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation. Nat. Biomed. Eng. 4, 69\u201383 (2020).","journal-title":"Nat. Biomed. Eng."},{"key":"770_CR93","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.conb.2019.05.005","volume":"59","author":"PJ Hamilton","year":"2019","unstructured":"Hamilton, P. J. & Nestler, E. J. Epigenetics and addiction. Curr. Opin. Neurobiol. 59, 128\u2013136 (2019).","journal-title":"Curr. Opin. Neurobiol."},{"key":"770_CR94","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41593-021-00814-8","volume":"24","author":"H Kronman","year":"2021","unstructured":"Kronman, H. et al. Long-term behavioral and cell-type-specific molecular effects of early life stress are mediated by H3K79me2 dynamics in medium spiny neurons. Nat. Neurosci. 24, 667\u2013676 (2021).","journal-title":"Nat. Neurosci."},{"key":"770_CR95","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.adq0031","volume":"18","author":"EJ Nestler","year":"2025","unstructured":"Nestler, E. J. The biology of addiction. Sci. Signal. 18, eadq0031 (2025).","journal-title":"Sci. Signal."},{"key":"770_CR96","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1001\/jamapsychiatry.2013.4291","volume":"71","author":"EJ Nestler","year":"2014","unstructured":"Nestler, E. J. Epigenetic mechanisms of depression. JAMA Psychiatry 71, 454\u2013456 (2014).","journal-title":"JAMA Psychiatry"},{"key":"770_CR97","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1056\/NEJMoa2405541","volume":"391","author":"CN Duncan","year":"2024","unstructured":"Duncan, C. N. et al. Hematologic cancer after gene therapy for cerebral adrenoleukodystrophy. N. Engl. J. Med. 391, 1287\u20131301 (2024).","journal-title":"N. Engl. J. Med."},{"key":"770_CR98","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/ana.23982","volume":"74","author":"JR Mendell","year":"2013","unstructured":"Mendell, J. R. et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann. Neurol. 74, 637\u2013647 (2013).","journal-title":"Ann. Neurol."},{"key":"770_CR99","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson, M. D. et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N. Engl. J. Med. 379, 22\u201331 (2018).","journal-title":"N. Engl. J. Med."},{"key":"770_CR100","doi-asserted-by":"publisher","first-page":"e2270","DOI":"10.1212\/WNL.0000000000009233","volume":"94","author":"DE Frank","year":"2020","unstructured":"Frank, D. E. et al. Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy. Neurology 94, e2270\u2013e2282 (2020).","journal-title":"Neurology"},{"key":"770_CR101","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","volume":"20","author":"JW Day","year":"2021","unstructured":"Day, J. W. et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 20, 284\u2013293 (2021).","journal-title":"Lancet Neurol."},{"key":"770_CR102","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/mus.27347","volume":"64","author":"KR Wagner","year":"2021","unstructured":"Wagner, K. R. et al. Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: a randomized, double-blind, placebo-controlled, dose-titration trial. Muscle Nerve 64, 285\u2013292 (2021).","journal-title":"Muscle Nerve"},{"key":"770_CR103","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1056\/NEJMoa2400442","volume":"391","author":"F Eichler","year":"2024","unstructured":"Eichler, F. et al. Lentiviral gene therapy for cerebral adrenoleukodystrophy. N. Engl. J. Med. 391, 1302\u20131312 (2024).","journal-title":"N. Engl. J. Med."},{"key":"770_CR104","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409134","author":"M Fontana","year":"2024","unstructured":"Fontana, M. et al. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2409134 (2024).","journal-title":"N. Engl. J. Med."},{"key":"770_CR105","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/ana.26755","volume":"94","author":"CM Zaidman","year":"2023","unstructured":"Zaidman, C. M. et al. Delandistrogene moxeparvovec gene therapy in ambulatory patients (aged \u22654 to <8 years) with Duchenne muscular dystrophy: 1-year interim results from study SRP-9001-103 (ENDEAVOR). Ann. Neurol. 94, 955\u2013968 (2023).","journal-title":"Ann. Neurol."},{"key":"770_CR106","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1001\/jama.2023.18688","volume":"330","author":"T Coelho","year":"2023","unstructured":"Coelho, T. et al. Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy. JAMA 330, 1448\u20131458 (2023).","journal-title":"JAMA"},{"key":"770_CR107","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/S0140-6736(21)02017-1","volume":"399","author":"F Fumagalli","year":"2022","unstructured":"Fumagalli, F. et al. Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1\/2 trial and expanded access. Lancet 399, 372\u2013383 (2022).","journal-title":"Lancet"},{"key":"770_CR108","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.addr.2020.06.013","volume":"157","author":"PM Glassman","year":"2020","unstructured":"Glassman, P. M. et al. Targeting drug delivery in the vascular system: focus on endothelium. Adv. Drug Deliv. Rev. 157, 96\u2013117 (2020).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"770_CR109","doi-asserted-by":"crossref","first-page":"433","DOI":"10.33588\/rn.4507.2007270","volume":"45","author":"AP Sempere","year":"2007","unstructured":"Sempere, A. P., Berenguer-Ruiz, L., Lezcano-Rodas, M., Mira-Berenguer, F. & Waez, M. [Lumbar puncture: its indications, contraindications, complications and technique]. Rev. Neurol. 45, 433\u2013436 (2007).","journal-title":"Rev. Neurol."},{"key":"770_CR110","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00190-19","volume":"33","author":"R Nau","year":"2020","unstructured":"Nau, R., Blei, C. & Eiffert, H. Intrathecal antibacterial and antifungal therapies. Clin. Microbiol. Rev. 33, e00190-19 (2020).","journal-title":"Clin. Microbiol. Rev."},{"key":"770_CR111","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.pmr.2022.01.004","volume":"33","author":"T Ericson","year":"2022","unstructured":"Ericson, T., Singla, P. & Kohan, L. Intrathecal pumps. Phys. Med. Rehabil. Clin. N. Am. 33, 409\u2013424 (2022).","journal-title":"Phys. Med. Rehabil. Clin. N. Am."},{"key":"770_CR112","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/ner.12693","volume":"21","author":"SJ Nagel","year":"2018","unstructured":"Nagel, S. J. et al. Intrathecal therapeutics: device design, access methods, and complication mitigation. Neuromodulation 21, 625\u2013640 (2018).","journal-title":"Neuromodulation"},{"key":"770_CR113","volume":"12","author":"ST Magill","year":"2020","unstructured":"Magill, S. T., Choy, W., Nguyen, M. P. & McDermott, M. W. Ommaya reservoir insertion: a technical note. Cureus 12, e7731 (2020).","journal-title":"Cureus"},{"key":"770_CR114","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1016\/S0140-6736(07)60982-9","volume":"369","author":"MG Kaplitt","year":"2007","unstructured":"Kaplitt, M. G. et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson\u2019s disease: an open label, phase I trial. Lancet 369, 2097\u20132105 (2007).","journal-title":"Lancet"},{"key":"770_CR115","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1158\/1078-0432.CCR-21-3324","volume":"28","author":"EHP van Putten","year":"2022","unstructured":"van Putten, E. H. P. et al. Convection enhanced delivery of the oncolytic adenovirus Delta24-RGD in patients with recurrent GBM: a phase I clinical trial including correlative studies. Clin. Cancer Res. 28, 1572\u20131585 (2022).","journal-title":"Clin. Cancer Res."},{"key":"770_CR116","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s13346-020-00891-5","volume":"12","author":"LA Keller","year":"2022","unstructured":"Keller, L. A., Merkel, O. & Popp, A. Intranasal drug delivery: opportunities and toxicologic challenges during drug development. Drug Deliv. Transl. Res. 12, 735\u2013757 (2022).","journal-title":"Drug Deliv. Transl. Res."},{"key":"770_CR117","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15010207","volume":"15","author":"VA Duong","year":"2023","unstructured":"Duong, V. A., Nguyen, T. T. & Maeng, H. J. Recent advances in intranasal liposomes for drug, gene, and vaccine delivery. Pharmaceutics 15, 207 (2023).","journal-title":"Pharmaceutics"},{"key":"770_CR118","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1056\/NEJMoa2308719","volume":"390","author":"AR Rezai","year":"2024","unstructured":"Rezai, A. R. et al. Ultrasound blood-brain barrier opening and Aducanumab in Alzheimer\u2019s disease. N. Engl. J. Med. 390, 55\u201362 (2024).","journal-title":"N. Engl. J. Med."},{"key":"770_CR119","doi-asserted-by":"publisher","first-page":"24139","DOI":"10.1021\/acsnano.4c05270","volume":"18","author":"G Kwak","year":"2024","unstructured":"Kwak, G. et al. Brain nucleic acid delivery and genome editing via focused ultrasound-mediated blood-brain barrier opening and long-circulating nanoparticles. ACS Nano 18, 24139\u201324153 (2024).","journal-title":"ACS Nano"}],"container-title":["Nature Reviews Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41570-025-00770-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41570-025-00770-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41570-025-00770-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T13:01:03Z","timestamp":1764853263000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41570-025-00770-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":119,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["770"],"URL":"https:\/\/doi.org\/10.1038\/s41570-025-00770-y","relation":{},"ISSN":["2397-3358"],"issn-type":[{"value":"2397-3358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"6 October 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.D. is a cofounder and holds equity in Immunanoengineering Therapeutics. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}